Cargando…

Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity

PURPOSE: To evaluate the efficacy of a biosimilar ranibizumab (Razumab) on outcomes of retinopathy of prematurity (ROP) for the first time. METHODS: This retrospective study included infants presenting with stage 3+ ROP either in zone 1 or zone 2 posterior or aggressive posterior ROP (APROP). All el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prajapati, Vipul, Choudhary, Tanvi, Chauhan, Wilhemina, Shah, Sonali, Handa, Ramya, Jahan, Bushra, Malviya, Sheetal, Sengupta, Sabyasachi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228963/ https://www.ncbi.nlm.nih.gov/pubmed/36727329 http://dx.doi.org/10.4103/ijo.IJO_973_22

Ejemplares similares

Commentary: Biosimilars in the treatment of retinopathy of prematurity
por: Soni, Tanvi, et al.
Publicado: (2023)

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
por: Menke, Marcel N, et al.
Publicado: (2015)

Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016)

Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography
por: Wu, Lei, et al.
Publicado: (2023)

Effect of ranibizumab on retinopathy of prematurity: A meta-analysis
por: Wang, Zhibin, et al.
Publicado: (2022)

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity
por: Patel, Samir N, et al.
Publicado: (2019)

Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity
por: Chandra, Parijat, et al.
Publicado: (2019)

Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis
por: Alva, Niza, et al.
Publicado: (2023)

Long-term peripheral retinal vascular behavior in retinopathy of prematurity patients treated with ranibizumab intravitreal injection as monotherapy using fluorescein angiography
por: Al Rasheed, Raghad, et al.
Publicado: (2022)

Combination of Intravitreal Ranibizumab and Laser Photocoagulation for Aggressive Posterior Retinopathy of Prematurity
por: Mota, Ágata, et al.
Publicado: (2012)

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy
por: Chan, Joyce J. T., et al.
Publicado: (2016)

Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment
por: Gotz-Więckowska, Anna, et al.
Publicado: (2017)

Intravitreal ranibizumab for retinopathy of prematurity: The ocular and systemic safety profile query
por: Al Kalbani, Khulood, et al.
Publicado: (2023)

Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity
por: Arámbulo, Odalis, et al.
Publicado: (2015)

Combination therapy of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity
por: Dudani, Ajay I, et al.
Publicado: (2022)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment
por: Huang, Qiujing, et al.
Publicado: (2017)

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior Retinopathy of Prematurity with Vitreous Hemorrhage
por: Xu, Yu, et al.
Publicado: (2016)

Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab
por: Tong, Qizhe, et al.
Publicado: (2018)

Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial
por: Fidler, Matthew, et al.
Publicado: (2020)

Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity
por: Gangwe, Anil Babanrao, et al.
Publicado: (2021)

Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity
por: Hoppe, Charis, et al.
Publicado: (2022)

Intravitreal ranibizumab as salvage therapy in an extremely low–birth-weight infant with rush type retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2012)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
por: Lin, Chun-Ju, et al.
Publicado: (2016)

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
por: Hu, Qinrui, et al.
Publicado: (2017)

COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY
por: Zhang, Guoming, et al.
Publicado: (2017)

Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity
por: Chen, Xuting, et al.
Publicado: (2019)

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019)

Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity
por: Cao, Jing-Ke, et al.
Publicado: (2023)

Comparison of OCT angiography in children with a history of intravitreal injection of ranibizumab versus laser photocoagulation for retinopathy of prematurity
por: Zhao, Jinfeng, et al.
Publicado: (2020)

Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity
por: Parchand, Swapnil M, et al.
Publicado: (2021)

Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
por: Shoeibi, Nasser, et al.
Publicado: (2018)

Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar
por: Kim, Eunji, et al.
Publicado: (2022)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
por: Arias, Luis, et al.
Publicado: (2016)

A Review of Ranibizumab for the Treatment of Diabetic Retinopathy
por: Stewart, Michael W.
Publicado: (2017)

Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial
por: Wu, Zhenquan, et al.
Publicado: (2022)

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment
por: Hatamnejad, Amin, et al.
Publicado: (2023)

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5gebojbg6uouu6nicjn3s48ju